Trial Profile
A retrospective study evaluating long-term efficacy and safety of plasma-derived human C1-INH concentrate in french population of patients from COBRA registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2017
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Angioedema; Hereditary angioedema
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2017 New trial record
- 06 Mar 2017 Results (n=16) assessing response to attack treatment in patients with drug-induced angioedema, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 01 Mar 2017 Results published in the European Journal of Dermatology